UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 106

Sortiert nach

Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers

PloS one, 2018-06, Vol.13 (6), p.e0198374-e0198374

2018

Volltextzugriff (PDF)

Glucose-Induced Conformational Changes in Glucokinase Mediate Allosteric Regulation: Transient Kinetic Analysis

Biochemistry (Easton), 2006-06, Vol.45 (24), p.7553-7562

2006

Volltextzugriff (PDF)

Liverome: a curated database of liver cancer-related gene signatures with self-contained context information

BMC genomics, 2011-11, Vol.12 Suppl 3 (Suppl 3), p.S3-S3, Article S3

2011

Volltextzugriff (PDF)

Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR

Bioorganic & medicinal chemistry letters, 2012-08, Vol.22 (15), p.5098-5103

2012

Volltextzugriff (PDF)

Biochemical Basis of Glucokinase Activation and the Regulation by Glucokinase Regulatory Protein in Naturally Occurring Mutations

The Journal of biological chemistry, 2006-12, Vol.281 (52), p.40201-40207

2006

Volltextzugriff (PDF)

Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors

Bioorganic & medicinal chemistry letters, 2011-02, Vol.21 (4), p.1270-1274

2011

Volltextzugriff (PDF)

Evidence for a Two-Base Mechanism Involving Tyrosine-265 from Arginine-219 Mutants of Alanine Racemase

Biochemistry (Easton), 1999-03, Vol.38 (13), p.4058-4065

1999

Volltextzugriff (PDF)

4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors

Bioorganic & medicinal chemistry letters, 2010-10, Vol.20 (20), p.6096-6099

2010

Volltextzugriff (PDF)

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity

Molecular cancer therapeutics, 2011-11, Vol.10 (11), p.2189-2199

2011

Volltextzugriff (PDF)

Pyridine-2-propanoic acids: Discovery of dual PPARα/γ agonists as antidiabetic agents

Bioorganic & medicinal chemistry letters, 2006-12, Vol.16 (23), p.6116-6119

2006

Volltextzugriff (PDF)

Pyridine-3-propanoic acids: Discovery of dual PPARα/γ agonists as antidiabetic agents

Bioorganic & medicinal chemistry letters, 2006-12, Vol.16 (23), p.6120-6123

2006

Volltextzugriff (PDF)

Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor α

The Journal of steroid biochemistry and molecular biology, 2002-07, Vol.81 (3), p.217-225

2002

Volltextzugriff (PDF)

Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series

Bioorganic & medicinal chemistry letters, 2013-05, Vol.23 (9), p.2787-2792

2013

Volltextzugriff (PDF)

Glucose Modulation of Glucokinase Activation by Small Molecules

Biochemistry (Easton), 2008-04, Vol.47 (17), p.5028-5036

2008

Volltextzugriff (PDF)

Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier

Molecular cancer therapeutics, 2012-01, Vol.11 (1), p.57-65

2012

Volltextzugriff (PDF)

Abstract 2570: Discovery of potent, selective, and orally available WEE1 inhibitors that demonstrate increased DNA damage and mitosis in tumor cells leading to tumor regression in vivo

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.2570-2570

2022

Volltextzugriff (PDF)

Biochemical Characterization of MODY2 Glucokinase Variants V62M and G72R Reveals Reduced Enzymatic Activities Relative to Wild Type

Biochemistry (Easton), 2009-03, Vol.48 (11), p.2514-2521

2009

Volltextzugriff (PDF)

Steady-State Kinetic and Inhibition Studies of the Mammalian Target of Rapamycin (mTOR) Kinase Domain and mTOR Complexes

Biochemistry (Easton), 2010-10, Vol.49 (39), p.8488-8498

2010

Volltextzugriff (PDF)

Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes

Journal of pharmacokinetics and pharmacodynamics, 2014-04, Vol.41 (2), p.127-139

2014

Volltextzugriff (PDF)

Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design

MedChemComm, 2010-08, Vol.1 (2), p.139

2010

Volltextzugriff (PDF)

Glucose modulation of glucokinase activation by small molecules

The FASEB journal, 2008-04, Vol.22 (S2), p.334-334

2008

Volltextzugriff (PDF)

Abstract 3492: A novel PI3K/mTOR dual inhibitor provides correlations of pharmacokinetic pharmacodynamic and tumor growth inhibition in a prostate PC3 xenograft model for application in clinical trials

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.3492-3492

2010

Volltextzugriff (PDF)

Corrigendum to “Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR” [Bioorg. Med. Chem. Lett. 22 (2012) 5098–5103]

Bioorganic & medicinal chemistry letters, 2012-11, Vol.22 (21), p.6774-6774

2012

Volltextzugriff (PDF)

Abstract 5043: Effects of a novel PI3 kinase/mTOR inhibitor on proliferation and pAKT signaling in canine lymphoma

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.5043-5043

2010

Volltextzugriff (PDF)

Abstract 5779: The discovery of the potent and selective PI3K/mTOR dual inhibitor PF-04691502 through structure-based drug design

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.5779-5779

2010

Volltextzugriff (PDF)

1 – 25 von 106

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(94)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers

Glucose-Induced Conformational Changes in Glucokinase Mediate Allosteric Regulation: Transient Kinetic Analysis

Liverome: a curated database of liver cancer-related gene signatures with self-contained context information

Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR

Biochemical Basis of Glucokinase Activation and the Regulation by Glucokinase Regulatory Protein in Naturally Occurring Mutations

Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors

Evidence for a Two-Base Mechanism Involving Tyrosine-265 from Arginine-219 Mutants of Alanine Racemase

4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity

Pyridine-2-propanoic acids: Discovery of dual PPARα/γ agonists as antidiabetic agents

Pyridine-3-propanoic acids: Discovery of dual PPARα/γ agonists as antidiabetic agents

Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor α

Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series

Glucose Modulation of Glucokinase Activation by Small Molecules

Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier

Abstract 2570: Discovery of potent, selective, and orally available WEE1 inhibitors that demonstrate increased DNA damage and mitosis in tumor cells leading to tumor regression in vivo

Biochemical Characterization of MODY2 Glucokinase Variants V62M and G72R Reveals Reduced Enzymatic Activities Relative to Wild Type

Steady-State Kinetic and Inhibition Studies of the Mammalian Target of Rapamycin (mTOR) Kinase Domain and mTOR Complexes

Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes

Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design

Glucose modulation of glucokinase activation by small molecules

Abstract 3492: A novel PI3K/mTOR dual inhibitor provides correlations of pharmacokinetic pharmacodynamic and tumor growth inhibition in a prostate PC3 xenograft model for application in clinical trials

Corrigendum to “Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR” [Bioorg. Med. Chem. Lett. 22 (2012) 5098–5103]

Abstract 5043: Effects of a novel PI3 kinase/mTOR inhibitor on proliferation and pAKT signaling in canine lymphoma

Abstract 5779: The discovery of the potent and selective PI3K/mTOR dual inhibitor PF-04691502 through structure-based drug design

Suchergebnisse filtern